UK MHRA grants marketing authorization to Telix’s prostate cancer PET imaging agent, Illuccix: Melbourne, Australia Friday, February 14, 2025, 10:00 Hrs [IST] Telix, a commercia ...

An emergency physician has pinpointed a trio of "worrying" symptoms that might signal a lethal cancer accountable for nearly ...

The Elekta Unity MR-LINAC system, used at Allegheny General Hospital, combines MRI imaging with radiation therapy to target cancerous cells with pinpoint precision.

Artera and Tempus are collaborating to expand access to Artera’s AI-based prostate cancer test. Currently connected to more ...

The primary endpoint is objective response rate, with progression-free survival a key secondary endpoint. The study includes a pre-registration step for arm determination by the molecular tumor board.

In the post-op SAKK 09/10 trial, only patients in the higher PORTOS score group benefited from radiation therapy dose escalation (clinical progression free survival HR 0.19, 95% CI 0.05-0.70; p = 0.01 ...

Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall ...

Prostate cancer is the leading cancer type in men. Getting screened can help you catch cancer early, when it’s easier to ...

PORTOS can determine which patients with localized prostate cancer will benefit from dose-escalation of radiotherapy, data suggest.

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the ...